Trial
KRAKEN (muvalaplin phase 2)
Status Completed, published JAMA 2025
233 participants with Lp(a) of 175 nmol/L or more and ASCVD, diabetes or FH took muvalaplin 10, 60 or 240 mg daily or placebo for 12 weeks: placebo-adjusted reductions of 47.6, 81.7 and 85.8 percent on an intact Lp(a) assay and 40.4, 70.0 and 68.9 percent on a traditional apo(a)-based assay; apoB fell up to 16 percent; hs-CRP unchanged; no safety concerns. Presented at AHA 2024.
Primary endpoint: placebo-adjusted percent change in Lp(a) molar concentration at week 12, on both assays. Led to MOVE-Lp(a) (NCT07157774).
Page updated 17 August 2026.